Table 3.

Adjusted and Unadjusted Single SNP Analysis Towards Mycophenolate Related Anemia

SNP no.	rs number	Gene Name	Unadjusted Hazard Ratio (95% CI)1	p-value	Adjusted Hazard Ratio (95% CI)2	p-value	MAF3
1	rs568408	IL12A	1.99 (1.40–2.83)	0.000124	1.98 (1.39–2.82)	0.000144	A	0.15
2	rs2037483	HUS15	0.58 (0.42–0.79)	0.00058	0.54 (0.39–0.74)	0.000164	A	0.50
3	rs1056663	HUS15	0.58 (0.43–0.80)	0.00068	0.54 (0.39–0.75)	0.000184	A	0.49
4	rs11572076	CYP2C86	3.44(1.90–6.25)	0.000054	3.24 (1.70–6.20)	0.000374	A	0.03
5	rs11572103	CYP2C86	3.40 (1.92–6.03)	0.000034	3.04 (1.61–5.73)	0.00059	T	0.03
6	rs5005	ADM	3.26 (1.62–6.57)	0.00090	3.52 (1.68–7.63)	0.00085	G	0.01
7	rs3797897	MSH3	1.95 (1.33–2.86)	0.00058	1.89 (1.28–2.79)	0.00137	G	0.09
8	rs12441817	CYP1A1	1.76 (1.24–2.50)	0.00143	1.77 (1.24–2.51)	0.00150	C	0.13
9	rs4135113	TDG	2.27 (1.28–4.01)	0.00479	2.48 (1.38–4.43)	0.00227	A	0.05
10	rs2227551	PLAU7	1.61 (1.20–2.17)	0.00166	1.57 (1.17–2.11)	0.00261	G	0.32
11	rs2239393	COMT	1.61 (1.20–2.17)	0.00155	1.57 (1.17–2.11)	0.00292	G	0.37
12	rs3087243	CTLA4	0.57 (0.40–0.79)	0.00093	0.60 (0.43–0.84)	0.00300	A	0.38
13	rs4633	COMT	0.61 (0.45–0.83)	0.00167	0.63 (0.46–0.85)	0.00301	T	0.48
14	rs610899	MRE11A8	1.48 (1.11–1.98)	0.00811	1.55 (1.16–2.07)	0.00322	G	0.42
15	rs4303	ACE	4.84 (2.03–11.6)	0.00038	3.74 (1.54–9.08)	0.00357	T	0.02
16	rs2227552	C10orf557	1.55 (1.14–2.11)	0.00504	1.57 (1.16–2.13)	0.00380	C	0.28
17	rs2010963	VEGFA	0.58 (0.40–0.84)	0.00364	0.58 (0.40–0.84)	0.00449	C	0.31
18	rs518276	MRE11A8	1.49 (1.13–1.98)	0.00527	1.50 (1.13–1.99)	0.00457	A	0.41
19	rs12922317	RUNDC2A	1.46 (1.09–1.95)	0.01046	1.50 (1.13–1.99)	0.00544	G	0.34
20	rs497763	ANKRD49	1.46 (1.09–1.95)	0.01086	1.51 (1.13–2.02)	0.00566	A	0.44
21	rs373496	TNFRSF17	2.83 (1.47–5.47)	0.00195	2.55 (1.31–4.96)	0.00572	T	0.03
22	rs3020314	ESR1	1.49 (1.11–1.99)	0.00713	1.50 (1.13–2.01)	0.00574	C	0.41
23	rs1272744	MRE11A8	1.50 (1.12–1.99)	0.00615	1.49 (1.12–1.99)	0.00675	C	0.40
24	rs1049631	IL4R	0.64 (0.47–0.87)	0.00464	0.65 (0.48–0.89)	0.00691	A	0.48
25	rs1056836	CYP1B1	0.70 (0.52–0.95)	0.02053	0.66 (0.48–0.89)	0.00694	G	0.48
26	rs2193587	DGKG	0.51 (0.33–0.79)	0.00279	0.55 (0.35–0.85)	0.00705	G	0.20
27	rs2740560	CYP3A79	1.71 (1.21–2.41)	0.00228	1.62 (1.14–2.31)	0.00716	A	0.18
28	rs2687140	CYP3A79	1.72 (1.22–2.42)	0.00206	1.62 (1.14–2.30)	0.00718	A	0.18
29	rs2074086	ABCC1	0.63 (0.45–0.88)	0.00637	0.63 (0.45–0.88)	0.00754	C	0.38
30	rs836802	MSH3	0.58 (0.38–0.88)	0.00988	0.56 (0.37–0.86)	0.00767	G	0.24
31	rs3813867	CYP2E1	2.10 (1.24–3.54)	0.00828	2.03 (1.2–3.42)	0.00552	C	0.04
32	rs1946519	IL18	0.66 (0.49–0.90)	0.00847	0.66 (0.49–0.90)	0.00955	A	0.40
33	rs943975	CYP2E1	1.65 (1.14–2.39)	0.00860	1.64 (1.13–2.36)	0.00764	C	0.16
34	rs20432	PTGS2	1.73 (1.19–2.51)	0.00909	1.54 (1.11–2.13)	0.00420	G	0.23
35	rs2802269	CDC42BPA	1.66 (1.11–2.49)	0.00953	1.74 (1.14–2.64)	0.01489	G	0.09
36	rs2020869	FMO2	1.71 (1.20–2.43)	0.00967	1.62 (1.12–2.33)	0.00317	G	0.15

¹SNPs are not adjusted for clinical factors,

²adjusted for antiviral use, age, weight, posttransplant dialysis, ²hazard and 95% confidence interval (CI) of developing anemia for each risk allele,

³allele associated with the hazard and the minor allele frequency (MAF) in the population,

⁴significant accounting for a FDR of 20%,

⁵HUS1 SNPs are correlated r²=1.0,

⁶CYP2C8 SNPs are correlated r²=0.93,

⁷PLAU and C10orf55 SNPs are correlated r²=0.93,

⁸MRE11A SNPs are correlated r²=0.89,

⁹CYP3A7 SNPs are correlated r² =0.99.